首个CDK4/6抑制剂帕博西尼的药理和临床综述

首个CDK4/6抑制剂帕博西尼的药理和临床综述

孙慧娟,张菊红,王丽丽,张建强▲

山东省药学科学院;,山东省药学科学院,山东省药学科学院,山东省福瑞达医药集团公司

收稿日期:2016-03-09 修回日期:2016-11-02 出版日期:2016-10-25 发布日期:2016-10-25

A Review of Pharmacological and Clinical Research of the First CDK4/6 Inhibitor Palbociclib

孙慧娟,张菊红,王丽丽 and

Shandong Academy of Pharmaceutical Sciences,Shandong Academy of Pharmaceutical Sciences,Shandong Academy of Pharmaceutical Sciences,

Received:2016-03-09 Revised:2016-11-02 Online:2016-10-25 Published:2016-10-25

摘要/Abstract

摘要： 本文介绍了帕博西尼和来曲唑联合用于治疗绝经后妇女对雌激素受体（ER）阳性，对人表皮生长因子受体2（HER2）阴性的晚期乳腺癌，作为转移性疾病的初始内分泌为基础的治疗的药理、药动学、临床研究和安全性信息。这些信息主要参考了国外有关的帕博西尼的注册和临床资料。临床试验表明帕博西尼和来曲唑联合应用能使患者的无进展生存期（PFS）明显提高。

Abstract: Pharmacology，pharmacokinetics，clinical study and safety of palbociclib in combination with letrozole in the treatment of postmenopausal women with estrogen receptor (ER)-positive， human epidermal growth factor receptor 2(HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease were introduced. The related registration and clinical data of palbociclib in foreign countries were referenced.Clinical trials demonstrated the Progression-Free-Survival (PFS) increased significantly in patients treated with palbociclib and letrozole.

孙慧娟,张菊红,王丽丽,张建强▲. 首个CDK4/6抑制剂帕博西尼的药理和临床综述[J]. .

孙慧娟,张菊红,王丽丽 and. A Review of Pharmacological and Clinical Research of the First CDK4/6 Inhibitor Palbociclib[J]. .